董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roni Mamluk | 女 | Director | 53 | 20.63万美元 | 未持股 | 2020-04-24 |
| Bard Geesaman | 男 | Director | 52 | 11.31万美元 | 未持股 | 2020-04-24 |
| John Scarlett | 男 | Director | 69 | 13.06万美元 | 未持股 | 2020-04-24 |
| Raj Kannan | 男 | Chief Executive Officer, Director | 56 | 641.33万美元 | 未持股 | 2020-04-24 |
| Todd Foley | 男 | Director | 48 | 12.21万美元 | 未持股 | 2020-04-24 |
| David Stack | 男 | Chairman of the Board | 68 | 15.11万美元 | 未持股 | 2020-04-24 |
| John F. Thero | 男 | Director | 59 | 12.81万美元 | 未持股 | 2020-04-24 |
| Todd Foley | 男 | Director | 48 | 未披露 | 未持股 | 2020-04-24 |
| Scott Minick | 男 | Director | 68 | 14.96万美元 | 未持股 | 2020-04-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anand Varadan | 男 | Executive Vice President, Chief Commercial Officer | 53 | 156.87万美元 | 未持股 | 2020-04-24 |
| Drew Enamait | 男 | Vice President, Finance and Administration | 45 | 33.28万美元 | 未持股 | 2020-04-24 |
| Raj Kannan | 男 | Chief Executive Officer, Director | 56 | 641.33万美元 | 未持股 | 2020-04-24 |
| William Ludlam | 男 | Senior Vice President, Clinical Development and Medical Affairs | 55 | 73.09万美元 | 未持股 | 2020-04-24 |
| Lee G. Giguere | 男 | Vice President, General Counsel | 40 | 49.95万美元 | 未持股 | 2020-04-24 |
| Mark J. Fitzpatrick | 男 | President | 57 | 134.63万美元 | 未持股 | 2020-04-24 |
董事简历
中英对照 | 中文 | 英文- Roni Mamluk
-
Roni Mamluk自2015年3月起担任公司的首席发展官。她于2013年4月-2015年3月担任公司的首席执行官，并担任不同的职位，承担着日益重要的责任，包括运营总监和研发副总裁（2006-2013年4月）。她也担任董事会成员（2013年4月-2015年3月）。自加入公司，Mamluk博士担任发展的领导职位，是公司专有的瞬态渗透增强剂（Transient Permeability Enhancer， TPE，技术平台）的主要发明者之一。她也领导着公司TPE平台的口服生长抑素的发展及持续改进。Mamluk博士从Adnexus Therapeutics股份有限公司（Adnexus Therapeutics,Inc）跳槽加入我们公司，建立并领导非临床研发。Mamluk博士拥有希伯来大学（Hebrew University）学士学位和博士学位。她也参加哈佛医学院儿童医院在血管生成领域的博士后课程。
Roni Mamluk joined our Board of Directors in June 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as our Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma Israel Ltd. since April 2017. Dr. Mamluk served as our Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013 including Chief Operating Officer and Vice President, Research and Development. She also served as a member of our Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children’s Hospital/Harvard Medical School in the field of angiogenesis. - Roni Mamluk自2015年3月起担任公司的首席发展官。她于2013年4月-2015年3月担任公司的首席执行官，并担任不同的职位，承担着日益重要的责任，包括运营总监和研发副总裁（2006-2013年4月）。她也担任董事会成员（2013年4月-2015年3月）。自加入公司，Mamluk博士担任发展的领导职位，是公司专有的瞬态渗透增强剂（Transient Permeability Enhancer， TPE，技术平台）的主要发明者之一。她也领导着公司TPE平台的口服生长抑素的发展及持续改进。Mamluk博士从Adnexus Therapeutics股份有限公司（Adnexus Therapeutics,Inc）跳槽加入我们公司，建立并领导非临床研发。Mamluk博士拥有希伯来大学（Hebrew University）学士学位和博士学位。她也参加哈佛医学院儿童医院在血管生成领域的博士后课程。
- Roni Mamluk joined our Board of Directors in June 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as our Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma Israel Ltd. since April 2017. Dr. Mamluk served as our Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013 including Chief Operating Officer and Vice President, Research and Development. She also served as a member of our Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children’s Hospital/Harvard Medical School in the field of angiogenesis.
- Bard Geesaman
-
Bard Geesaman在2004年加入董事会。2012年1月Geesaman博士在MPM担任总经理。2012-2015年他成为X PRIZE Foundation的生命科学执行董事。他是Solasia Pharma K.K。（一家特别制药公司，开发和商业化治疗癌症药物）的创立者。2003-2007年他担任Elixir Pharmaceuticals股份有限公司（Elixir Pharmaceuticals Inc.）的医疗发展副总裁，监督药物开发的临床战略和人类基因项目，也是公司商务拓展团队的成员。Geesaman博士是F2 和 F3 Ventures（两家总部在英国（UK）的风险资本基金）的一般合伙人，2004年起在两家公司的董事会工作。他在2000年通过内部医疗董事认证，后来完成了马萨诸塞州总医院（Massachusetts General Hospital）的临床学业。他拥有麻省理工学院（MIT）博士学位、哈佛医学院（Harvard Medical School）硕士学位和加尼福尼亚大学伯克利分校（University of California, Berkeley）学士学位。
Bard Geesaman joined our Board of Directors in 2004. Dr. Geesaman was at MPM Capital for over a decade before leaving in December 2018. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Dr. Geesaman founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Dr. Geesaman joined Centagenetix, an MPM-founded company exploring the genetics of successful aging. In 2006 Dr. Geesaman joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan which listed on the Tokyo Mothers exchange in March 2017. Dr. Geesaman is also the co-founder and a board member of MPM healthcare IT startup TriNetX big data analytics for clinical trials. Dr. Geesaman is passionate about innovation in health care, and in 2008 took a two-year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation. Dr. Geesaman became board certified in Internal Medicine in 2000 after completing a Clinical Fellowship at the Massachusetts General Hospital. He received his Ph.D. from MIT, an M.D. from Harvard Medical School and a B.S. from University of California, Berkeley. - Bard Geesaman在2004年加入董事会。2012年1月Geesaman博士在MPM担任总经理。2012-2015年他成为X PRIZE Foundation的生命科学执行董事。他是Solasia Pharma K.K。（一家特别制药公司，开发和商业化治疗癌症药物）的创立者。2003-2007年他担任Elixir Pharmaceuticals股份有限公司（Elixir Pharmaceuticals Inc.）的医疗发展副总裁，监督药物开发的临床战略和人类基因项目，也是公司商务拓展团队的成员。Geesaman博士是F2 和 F3 Ventures（两家总部在英国（UK）的风险资本基金）的一般合伙人，2004年起在两家公司的董事会工作。他在2000年通过内部医疗董事认证，后来完成了马萨诸塞州总医院（Massachusetts General Hospital）的临床学业。他拥有麻省理工学院（MIT）博士学位、哈佛医学院（Harvard Medical School）硕士学位和加尼福尼亚大学伯克利分校（University of California, Berkeley）学士学位。
- Bard Geesaman joined our Board of Directors in 2004. Dr. Geesaman was at MPM Capital for over a decade before leaving in December 2018. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Dr. Geesaman founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Dr. Geesaman joined Centagenetix, an MPM-founded company exploring the genetics of successful aging. In 2006 Dr. Geesaman joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan which listed on the Tokyo Mothers exchange in March 2017. Dr. Geesaman is also the co-founder and a board member of MPM healthcare IT startup TriNetX big data analytics for clinical trials. Dr. Geesaman is passionate about innovation in health care, and in 2008 took a two-year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation. Dr. Geesaman became board certified in Internal Medicine in 2000 after completing a Clinical Fellowship at the Massachusetts General Hospital. He received his Ph.D. from MIT, an M.D. from Harvard Medical School and a B.S. from University of California, Berkeley.
- John Scarlett
-
John Scarlett在2015年2月加入公司董事会。 Scarlett博士自2011年9月起成为Geron 公司（Geron Corporation NASDAQ： GERN，一家生物技术公司）的首席执行官和董事，2012年1月成为总裁。先前，他是Proteolix股份有限公司（Proteolix, Inc.，一家生物技术公司，兼并了Onyx Pharmaceuticals股份有限公司（Onyx Pharmaceuticals, Inc. （NASDAQ： ONXX））的总裁和首席执行官（2009年10月），也是Tercica股份有限公司（Tercica, Inc. （NASDAQ： TRCA）），2008年被Ipsen S.A.收购）的创立者和首席执行官。1993-2001年Scarlett博士成为Sensus Drug Development公司（Sensus Drug Development Corporation，2001年被Pharmacia公司（Pharmacia Corporation）收购）的创立者和首席执行官。他还联合创立了Covance Biotechnology Services股份有限公司（Covance Biotechnology Services, Inc.，一家合同生物制品制造和业务流程开发公司，2001年被Akzo Nobel’s Diosynth 部门收购）。在他的早期职业生涯中，他在McNeil Pharmaceutical（Johnson & Johnson和Novo Nordisk股份有限公司（Novo Nordisk Inc.）的子公司）工作。他取得厄勒姆学院（Earlham College）学士学位和芝加哥大学Pritzker医学院（University of Chicago, Pritzker School of Medicine）硕士学位。他完成了宾夕法尼亚大学（University of Pennsylvania）医院的内部医师培训和科罗拉多大学健康科学中心（University of Colorado Health Sciences Center）内分泌与代谢学业。
John Scarlett joined our Board of Directors in February 2015. Dr. Scarlett has been Chief Executive Officer and director of Geron Corporation NASDAQ: GERN, a biotechnology company, since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Previously, he was the President and Chief Executive Officer of Proteolix, Inc., a biotechnology company that merged with Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) in October 2009 and a founder and Chief Executive Officer of Tercica, Inc. (NASDAQ: TRCA), which was acquired by Ipsen S.A. (EPN: IPN) in 2008. From 1993 to 2001 Dr. Scarlett was also the founder and Chief Executive Officer of Sensus Drug Development Corporation, which was acquired by Pharmacia Corporation in 2001 and co-founded Covance Biotechnology Services, Inc., a contract biologics manufacturing and process development business that was acquired by Akzo Nobel’s (OTCMKTS: AKZOY) Diosynth Division in 2001. Earlier in his career, he worked for McNeil Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), and Novo Nordisk Inc. (NYSE: NVO). Dr. Scarlett currently serves on the board of Cytomx Therapeutics, Inc. (NASDAQ: CTMX). He received his B.A. from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. He completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center. - John Scarlett在2015年2月加入公司董事会。 Scarlett博士自2011年9月起成为Geron 公司（Geron Corporation NASDAQ： GERN，一家生物技术公司）的首席执行官和董事，2012年1月成为总裁。先前，他是Proteolix股份有限公司（Proteolix, Inc.，一家生物技术公司，兼并了Onyx Pharmaceuticals股份有限公司（Onyx Pharmaceuticals, Inc. （NASDAQ： ONXX））的总裁和首席执行官（2009年10月），也是Tercica股份有限公司（Tercica, Inc. （NASDAQ： TRCA）），2008年被Ipsen S.A.收购）的创立者和首席执行官。1993-2001年Scarlett博士成为Sensus Drug Development公司（Sensus Drug Development Corporation，2001年被Pharmacia公司（Pharmacia Corporation）收购）的创立者和首席执行官。他还联合创立了Covance Biotechnology Services股份有限公司（Covance Biotechnology Services, Inc.，一家合同生物制品制造和业务流程开发公司，2001年被Akzo Nobel’s Diosynth 部门收购）。在他的早期职业生涯中，他在McNeil Pharmaceutical（Johnson & Johnson和Novo Nordisk股份有限公司（Novo Nordisk Inc.）的子公司）工作。他取得厄勒姆学院（Earlham College）学士学位和芝加哥大学Pritzker医学院（University of Chicago, Pritzker School of Medicine）硕士学位。他完成了宾夕法尼亚大学（University of Pennsylvania）医院的内部医师培训和科罗拉多大学健康科学中心（University of Colorado Health Sciences Center）内分泌与代谢学业。
- John Scarlett joined our Board of Directors in February 2015. Dr. Scarlett has been Chief Executive Officer and director of Geron Corporation NASDAQ: GERN, a biotechnology company, since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Previously, he was the President and Chief Executive Officer of Proteolix, Inc., a biotechnology company that merged with Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) in October 2009 and a founder and Chief Executive Officer of Tercica, Inc. (NASDAQ: TRCA), which was acquired by Ipsen S.A. (EPN: IPN) in 2008. From 1993 to 2001 Dr. Scarlett was also the founder and Chief Executive Officer of Sensus Drug Development Corporation, which was acquired by Pharmacia Corporation in 2001 and co-founded Covance Biotechnology Services, Inc., a contract biologics manufacturing and process development business that was acquired by Akzo Nobel’s (OTCMKTS: AKZOY) Diosynth Division in 2001. Earlier in his career, he worked for McNeil Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), and Novo Nordisk Inc. (NYSE: NVO). Dr. Scarlett currently serves on the board of Cytomx Therapeutics, Inc. (NASDAQ: CTMX). He received his B.A. from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. He completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center.
- Raj Kannan
-
Raj Kannan于2019年6月17日成为我们的首席执行官并加入我们的董事会。Kannan先生自2018年7月起从KiniksaPharmaceuticals，Ltd.Kiniksa”；（纳斯达克股票代码:KNSA）加入我们公司，担任首席商务官。在该职位上，他负责建立和领导公司的商业运营，包括销售、市场营销、业务分析和市场准入功能。任职Kiniksa公司之前，他曾担任Merck KGaA公司的神经学和免疫学（“；n&i”；）业务特许经营全球主管，在那里他负责20亿美元的年收入。在该职位上，他成功领导了Mavenclad（多发性硬化症的口服小分子）的推出。他还担任N&I特许经营领导团队主席，该团队负责推进免疫学管道资产，优先考虑投资组合组合，并在开发资产之间分配资源。在Merck KGaA之前，Kannan先生在Boehringer Ingelheim（“；Boehringer”；）工作了十年，在美国，加拿大和德国担任越来越重要的职务，包括心血管专营权的全球营销主管，在那里他负责超过35亿美元的年收入。任职Boehringer公司之前，他曾任职Merck and Co.近十年，担任多种职务，从现场销售到美国高级营销经理。Kannan先生领导或支持了在美国和全球治疗领域的多个成功发布。Kannan先生在马德拉斯大学（University of Madras）获得化学学士学位，在东卡罗莱纳大学（East Carolina University）获得工商管理硕士学位。
Raj Kannan became our Chief Executive Officer and joined our Board of Directors on June 17 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. “Kiniksa” (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University. - Raj Kannan于2019年6月17日成为我们的首席执行官并加入我们的董事会。Kannan先生自2018年7月起从KiniksaPharmaceuticals，Ltd.Kiniksa”；（纳斯达克股票代码:KNSA）加入我们公司，担任首席商务官。在该职位上，他负责建立和领导公司的商业运营，包括销售、市场营销、业务分析和市场准入功能。任职Kiniksa公司之前，他曾担任Merck KGaA公司的神经学和免疫学（“；n&i”；）业务特许经营全球主管，在那里他负责20亿美元的年收入。在该职位上，他成功领导了Mavenclad（多发性硬化症的口服小分子）的推出。他还担任N&I特许经营领导团队主席，该团队负责推进免疫学管道资产，优先考虑投资组合组合，并在开发资产之间分配资源。在Merck KGaA之前，Kannan先生在Boehringer Ingelheim（“；Boehringer”；）工作了十年，在美国，加拿大和德国担任越来越重要的职务，包括心血管专营权的全球营销主管，在那里他负责超过35亿美元的年收入。任职Boehringer公司之前，他曾任职Merck and Co.近十年，担任多种职务，从现场销售到美国高级营销经理。Kannan先生领导或支持了在美国和全球治疗领域的多个成功发布。Kannan先生在马德拉斯大学（University of Madras）获得化学学士学位，在东卡罗莱纳大学（East Carolina University）获得工商管理硕士学位。
- Raj Kannan became our Chief Executive Officer and joined our Board of Directors on June 17 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. “Kiniksa” (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.
- Todd Foley
-
Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Todd Foley has served as a member of our board of directors since December 2018. Mr. Foley is a Managing Director at MPM Capital LLC, a healthcare-focused venture capital firm, which he joined in 1999. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards as well as several other privately-held life sciences and pharmaceutical companies, including Repare Therapeutics Inc., Aktis Oncology, Inc., CODA Biotherapeutics Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. In addition, Mr. Foley currently serves as President of Turmeric Acquisition Corp., a recently founded special purpose acquisition company. Mr. Foley received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. - Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Todd Foley has served as a member of our board of directors since December 2018. Mr. Foley is a Managing Director at MPM Capital LLC, a healthcare-focused venture capital firm, which he joined in 1999. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards as well as several other privately-held life sciences and pharmaceutical companies, including Repare Therapeutics Inc., Aktis Oncology, Inc., CODA Biotherapeutics Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. In addition, Mr. Foley currently serves as President of Turmeric Acquisition Corp., a recently founded special purpose acquisition company. Mr. Foley received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
- David Stack
-
David Stack，自2007年 11月起担任我们的总裁，首席执行官和董事。在2013年6月他被人民各位董事长。他自2005年起是MPM Capital（一家私人控股公司）的经营董事，自1998年起是Stack Pharmaceuticals股份有限公司（一个商业化、市场营销和战略公司）的经营董事。从2001年到2004年他是The Medicines公司NASDAQ： MDCO的总裁和首席执行官。先前，他是Innovex股份有限公司的总裁和总经理。他Congo1993年到1995年是Immunomedics的业务拓展/营销副总裁。在那之前，他从1981年到1993年在Roche Laboratories担任着日益重要的职位，包括治疗传染病的世界领先者，有关传染性疾病，肿瘤学和病毒学业务发展和规划董事。他目前在PepTx股份有限公司，Medivo股份有限公司和Amarin Corporation plc 担任董事会的一员。他从2006年到2010年是Molecular Insight Pharmaceuticals股份有限公司（NASDAQ： MIPI）董事会的一员，1999年到2010年是BioClinica股份有限公司（NASDAQ： BIOC）董事会的一员。他拥有Albany药学院药学学士学位和Siena学院生物学学士学位。
David Stack joined Amarin as a non-executive director in December 2012. Mr. Stack is currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr. Stack was a managing director of MPM Capital from 2005 until 2017 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004 he was President and Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories from 1981 until 1993 in various positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., Chiasma, Inc. and Prognos AI. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010. Mr. Stack holds a B.S. in Pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. - David Stack，自2007年 11月起担任我们的总裁，首席执行官和董事。在2013年6月他被人民各位董事长。他自2005年起是MPM Capital（一家私人控股公司）的经营董事，自1998年起是Stack Pharmaceuticals股份有限公司（一个商业化、市场营销和战略公司）的经营董事。从2001年到2004年他是The Medicines公司NASDAQ： MDCO的总裁和首席执行官。先前，他是Innovex股份有限公司的总裁和总经理。他Congo1993年到1995年是Immunomedics的业务拓展/营销副总裁。在那之前，他从1981年到1993年在Roche Laboratories担任着日益重要的职位，包括治疗传染病的世界领先者，有关传染性疾病，肿瘤学和病毒学业务发展和规划董事。他目前在PepTx股份有限公司，Medivo股份有限公司和Amarin Corporation plc 担任董事会的一员。他从2006年到2010年是Molecular Insight Pharmaceuticals股份有限公司（NASDAQ： MIPI）董事会的一员，1999年到2010年是BioClinica股份有限公司（NASDAQ： BIOC）董事会的一员。他拥有Albany药学院药学学士学位和Siena学院生物学学士学位。
- David Stack joined Amarin as a non-executive director in December 2012. Mr. Stack is currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr. Stack was a managing director of MPM Capital from 2005 until 2017 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004 he was President and Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories from 1981 until 1993 in various positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., Chiasma, Inc. and Prognos AI. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010. Mr. Stack holds a B.S. in Pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College.
- John F. Thero
-
John F. Thero，2009年11月加入Amarin。他被董事会任命为总裁兼首席执行官，此任命生效于2014年1月。在晋升之前，他自2010年11月起开始担任Amarin的总裁，且在更早前担任该公司的首席财务官。他拥有20多年的高级财务和运营管理经验，包括在生命科学公司的15多年的成长经历。他成功实现了企业的业务增长和销售业绩的提高。2007年，他曾担任ViaCell,Inc的首席财务官，带领公司的销售。并在2003至2007年间担任Acusphere,Inc的高级副总裁，监督制造业务的成功开展。1994年到2003年，他在Abiomed, Inc担任多项高级职位，包括业务运营部高级副总裁兼首席财务官，帮助公司从成长型企业转变为成熟型企业。其职业生涯始于 Arthur Andersen LLP，并在任职期间成为注册会计师。
John F. Thero joined Amarin in November 2009. He was promoted to President and Chief Executive Officer, and appointed to the Board, effective January 2014. Prior to his promotion, he was Amarin’s President since November 2010 before which he was Amarin’s Chief Financial Officer. Mr. Thero has more than 30 years of senior financial and operational management experience, including supporting the growth of life science companies for over 20 years. Prior to Amarin, Mr. Thero also served in a variety of roles and has helped manage both the successful commercial growth and the successful sale of companies between 1994 and 2007. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant. He currently serves as a member of the board of directors of Chiasma, Inc. He received a B.A. in Economics from the College of the Holy Cross. In 2019 Mr. Thero was named Ernst & Young LLP Entrepreneur of the Year for Life Sciences. - John F. Thero，2009年11月加入Amarin。他被董事会任命为总裁兼首席执行官，此任命生效于2014年1月。在晋升之前，他自2010年11月起开始担任Amarin的总裁，且在更早前担任该公司的首席财务官。他拥有20多年的高级财务和运营管理经验，包括在生命科学公司的15多年的成长经历。他成功实现了企业的业务增长和销售业绩的提高。2007年，他曾担任ViaCell,Inc的首席财务官，带领公司的销售。并在2003至2007年间担任Acusphere,Inc的高级副总裁，监督制造业务的成功开展。1994年到2003年，他在Abiomed, Inc担任多项高级职位，包括业务运营部高级副总裁兼首席财务官，帮助公司从成长型企业转变为成熟型企业。其职业生涯始于 Arthur Andersen LLP，并在任职期间成为注册会计师。
- John F. Thero joined Amarin in November 2009. He was promoted to President and Chief Executive Officer, and appointed to the Board, effective January 2014. Prior to his promotion, he was Amarin’s President since November 2010 before which he was Amarin’s Chief Financial Officer. Mr. Thero has more than 30 years of senior financial and operational management experience, including supporting the growth of life science companies for over 20 years. Prior to Amarin, Mr. Thero also served in a variety of roles and has helped manage both the successful commercial growth and the successful sale of companies between 1994 and 2007. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant. He currently serves as a member of the board of directors of Chiasma, Inc. He received a B.A. in Economics from the College of the Holy Cross. In 2019 Mr. Thero was named Ernst & Young LLP Entrepreneur of the Year for Life Sciences.
- Todd Foley
-
Todd Foley，2012年5月以来，他担任我们董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Todd Foley joined our Board of Directors in May 2008. Mr. Foley is a managing director with MPM Capital, a venture capital firm, or MPM, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards, including Rhythm Therapeutics NASDAQ: RYTM, Repare Therapeutics, Inc., CODA Biotherapeutics Inc., Entrada Therapeutics, Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. Mr. Foley previously served on the boards of Celladon Corporation from 2012 to 2014 Proteon Therapeutics, Inc. from 2012 to 2014 and Zalicus, Inc. from 2009 to 2013. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology, or MIT, and an M.B.A. from Harvard Business School. - Todd Foley，2012年5月以来，他担任我们董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Todd Foley joined our Board of Directors in May 2008. Mr. Foley is a managing director with MPM Capital, a venture capital firm, or MPM, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards, including Rhythm Therapeutics NASDAQ: RYTM, Repare Therapeutics, Inc., CODA Biotherapeutics Inc., Entrada Therapeutics, Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. Mr. Foley previously served on the boards of Celladon Corporation from 2012 to 2014 Proteon Therapeutics, Inc. from 2012 to 2014 and Zalicus, Inc. from 2009 to 2013. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology, or MIT, and an M.B.A. from Harvard Business School.
- Scott Minick
-
Scott Minick，2010年1月以来开始担任我们的总裁兼首席执行官，自2010年以来成为我们的董事会的成员。1998年到2010年1月，他是ARCH Venture Partners公司（一个风险投资公司，并在启动时，众多拱投资组合公司的发展和融资，包括绑定疗法）总经理。1995年到1998年，Minick先生是SEQUUS Pharmaceuticals公司（生物制药公司，被ALZA收购公司）总裁兼首席运营官。他在索尔克研究所神经生物学研究生培训，持有西北大学mba学位和圣地亚哥加州大学的学士学位。
Scott Minick joined our Board of Directors in October 2007. From January 2010 to March 2015 Mr. Minick served as President and Chief Executive Officer of BIND Therapeutics, Inc. NASDAQ: BIND, or BIND, a biopharmaceutical company. From 1998 to 2010 Mr. Minick was Managing Director of ARCH Venture Partners, or ARCH, and from 2010 to the present he has been Venture Partner of ARCH, where he was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND and Chiasma. From 1995 to 1998 Mr. Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation. Mr. Minick was formerly an executive at Baxter International, Inc. (NYSE: BAX) and Eli Lilly & Company (NYSE: LLY). He serves as a member of the board of directors of Alzheon, Inc. and Aira Tech Corp., served as a member of the board of directors of BIND from 2007 to 2015 and is a trustee of Beth Israel Deaconess Medical Center. Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego. - Scott Minick，2010年1月以来开始担任我们的总裁兼首席执行官，自2010年以来成为我们的董事会的成员。1998年到2010年1月，他是ARCH Venture Partners公司（一个风险投资公司，并在启动时，众多拱投资组合公司的发展和融资，包括绑定疗法）总经理。1995年到1998年，Minick先生是SEQUUS Pharmaceuticals公司（生物制药公司，被ALZA收购公司）总裁兼首席运营官。他在索尔克研究所神经生物学研究生培训，持有西北大学mba学位和圣地亚哥加州大学的学士学位。
- Scott Minick joined our Board of Directors in October 2007. From January 2010 to March 2015 Mr. Minick served as President and Chief Executive Officer of BIND Therapeutics, Inc. NASDAQ: BIND, or BIND, a biopharmaceutical company. From 1998 to 2010 Mr. Minick was Managing Director of ARCH Venture Partners, or ARCH, and from 2010 to the present he has been Venture Partner of ARCH, where he was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND and Chiasma. From 1995 to 1998 Mr. Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation. Mr. Minick was formerly an executive at Baxter International, Inc. (NYSE: BAX) and Eli Lilly & Company (NYSE: LLY). He serves as a member of the board of directors of Alzheon, Inc. and Aira Tech Corp., served as a member of the board of directors of BIND from 2007 to 2015 and is a trustee of Beth Israel Deaconess Medical Center. Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego.
高管简历
中英对照 | 中文 | 英文- Anand Varadan
Anand Varadan加入Chiasma, Inc. (Chiasma, Inc.)。2020年4月担任执行副总裁兼首席商务官，此前曾担任Chiasma, Inc.。2015年8月至2016年6月担任首席商务官。最近，Varadan先生通过他的咨询公司Ignition Insights, LLC(自2016年6月起运营)向公司以及各种其他生物技术公司和投资者提供商业和战略咨询服务。从2018年6月到2019年7月，Varadan先生担任Karyopharm Therapeutics, Inc.的执行副总裁兼首席商务官。纳斯达克:KPTI，一家专注于肿瘤学的制药公司。1999年1月至2015年7月，他在生物制药公司Amgen Inc.(纳斯达克股票代码:AMGN)担任商业领导和一般管理职务，包括2014年4月至2015年7月担任炎症和肾脏病业务部副总裁，2011年9月至2014年4月担任Amgen Canada副总裁/总经理。加入Amgen之前，他是Procter and Gamble Company (NYSE: PG)的品牌经理。他持有the Simon Business School at the University of Rochester的工商管理硕士学位和the George Washington University的动物学学士学位。
Anand Varadan joined Chiasma, Inc. as Chiasma, Inc. Executive Vice President, Chief Commercial Officer in April 2020 and previously served as Chiasma, Inc. Chief Commercial Officer from August 2015 to June 2016. Most recently, Mr. Varadan provided commercial and strategic consultancy services to the Company as well as a variety of other biotech companies and investors through his consulting firm, Ignition Insights, LLC, which he has operated since June 2016. From June 2018 to July 2019 Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc. NASDAQ: KPTI, an oncology-focused pharmaceutical company. From January 1999 to July 2015 he served in a progression of commercial leadership and general management roles at Amgen Inc. (NASDAQ: AMGN), a biopharmaceutical company, including Vice President, Inflammation and Nephrology Business Unit from April 2014 to July 2015 and Vice President/General Manager, Amgen Canada from September 2011 to April 2014. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company (NYSE: PG). Mr. Varadan received an M.B.A. from the Simon Business School at the University of Rochester and a B.A. in Zoology from The George Washington University.- Anand Varadan加入Chiasma, Inc. (Chiasma, Inc.)。2020年4月担任执行副总裁兼首席商务官，此前曾担任Chiasma, Inc.。2015年8月至2016年6月担任首席商务官。最近，Varadan先生通过他的咨询公司Ignition Insights, LLC(自2016年6月起运营)向公司以及各种其他生物技术公司和投资者提供商业和战略咨询服务。从2018年6月到2019年7月，Varadan先生担任Karyopharm Therapeutics, Inc.的执行副总裁兼首席商务官。纳斯达克:KPTI，一家专注于肿瘤学的制药公司。1999年1月至2015年7月，他在生物制药公司Amgen Inc.(纳斯达克股票代码:AMGN)担任商业领导和一般管理职务，包括2014年4月至2015年7月担任炎症和肾脏病业务部副总裁，2011年9月至2014年4月担任Amgen Canada副总裁/总经理。加入Amgen之前，他是Procter and Gamble Company (NYSE: PG)的品牌经理。他持有the Simon Business School at the University of Rochester的工商管理硕士学位和the George Washington University的动物学学士学位。
- Anand Varadan joined Chiasma, Inc. as Chiasma, Inc. Executive Vice President, Chief Commercial Officer in April 2020 and previously served as Chiasma, Inc. Chief Commercial Officer from August 2015 to June 2016. Most recently, Mr. Varadan provided commercial and strategic consultancy services to the Company as well as a variety of other biotech companies and investors through his consulting firm, Ignition Insights, LLC, which he has operated since June 2016. From June 2018 to July 2019 Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc. NASDAQ: KPTI, an oncology-focused pharmaceutical company. From January 1999 to July 2015 he served in a progression of commercial leadership and general management roles at Amgen Inc. (NASDAQ: AMGN), a biopharmaceutical company, including Vice President, Inflammation and Nephrology Business Unit from April 2014 to July 2015 and Vice President/General Manager, Amgen Canada from September 2011 to April 2014. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company (NYSE: PG). Mr. Varadan received an M.B.A. from the Simon Business School at the University of Rochester and a B.A. in Zoology from The George Washington University.
- Drew Enamait
Drew Enamait自2016年11月以来一直担任我们的Vice President，财务和行政以及首席会计官。此前，Enamait先生自2015年10月起担任公司的公司财务总监。在加入公司之前，他担任过各种职责递增的职务，最终担任LemaitreVascular，Inc.的高级财务总监。NASDAQ:LMAT，一家公共医疗器械公司，从2008年4月到2015年10月。Enamait先生还在Thermo Fisher Scientific，Inc.（NYSE:TMO）担任业务单元财务总监和内部审计经理。Enamait先生在Arthur Andersen LLP开始了他的职业生涯。Enamait先生于1996年在本特利学院（Bentley College）获得会计学学士学位，辅修法律，并于1999年在康涅狄格州获得注册会计师证书。
Drew Enamait has been our Vice President, Finance & Administration and principal accounting officer since November 2016. Previously, Mr. Enamait served as the Company’s Corporate Controller since October 2015. Prior to joining the Company, he served in various roles of increasing responsibility culminating in the position of Senior Controller, of LeMaitre Vascular, Inc. NASDAQ:LMAT, a public medical device company, from April 2008 to October 2015. Mr. Enamait also served as a business unit Finance Director and the Manager of Internal Audit at Thermo Fisher Scientific, Inc. (NYSE: TMO). Mr. Enamait began his professional career at Arthur Andersen LLP. Mr. Enamait received his B.S. in Accountancy, minor in Law from Bentley College in 1996 and earned a Certified Public Accountant certificate in the State of Connecticut in 1999.- Drew Enamait自2016年11月以来一直担任我们的Vice President，财务和行政以及首席会计官。此前，Enamait先生自2015年10月起担任公司的公司财务总监。在加入公司之前，他担任过各种职责递增的职务，最终担任LemaitreVascular，Inc.的高级财务总监。NASDAQ:LMAT，一家公共医疗器械公司，从2008年4月到2015年10月。Enamait先生还在Thermo Fisher Scientific，Inc.（NYSE:TMO）担任业务单元财务总监和内部审计经理。Enamait先生在Arthur Andersen LLP开始了他的职业生涯。Enamait先生于1996年在本特利学院（Bentley College）获得会计学学士学位，辅修法律，并于1999年在康涅狄格州获得注册会计师证书。
- Drew Enamait has been our Vice President, Finance & Administration and principal accounting officer since November 2016. Previously, Mr. Enamait served as the Company’s Corporate Controller since October 2015. Prior to joining the Company, he served in various roles of increasing responsibility culminating in the position of Senior Controller, of LeMaitre Vascular, Inc. NASDAQ:LMAT, a public medical device company, from April 2008 to October 2015. Mr. Enamait also served as a business unit Finance Director and the Manager of Internal Audit at Thermo Fisher Scientific, Inc. (NYSE: TMO). Mr. Enamait began his professional career at Arthur Andersen LLP. Mr. Enamait received his B.S. in Accountancy, minor in Law from Bentley College in 1996 and earned a Certified Public Accountant certificate in the State of Connecticut in 1999.
- Raj Kannan
Raj Kannan于2019年6月17日成为我们的首席执行官并加入我们的董事会。Kannan先生自2018年7月起从KiniksaPharmaceuticals，Ltd.Kiniksa”；（纳斯达克股票代码:KNSA）加入我们公司，担任首席商务官。在该职位上，他负责建立和领导公司的商业运营，包括销售、市场营销、业务分析和市场准入功能。任职Kiniksa公司之前，他曾担任Merck KGaA公司的神经学和免疫学（“；n&i”；）业务特许经营全球主管，在那里他负责20亿美元的年收入。在该职位上，他成功领导了Mavenclad（多发性硬化症的口服小分子）的推出。他还担任N&I特许经营领导团队主席，该团队负责推进免疫学管道资产，优先考虑投资组合组合，并在开发资产之间分配资源。在Merck KGaA之前，Kannan先生在Boehringer Ingelheim（“；Boehringer”；）工作了十年，在美国，加拿大和德国担任越来越重要的职务，包括心血管专营权的全球营销主管，在那里他负责超过35亿美元的年收入。任职Boehringer公司之前，他曾任职Merck and Co.近十年，担任多种职务，从现场销售到美国高级营销经理。Kannan先生领导或支持了在美国和全球治疗领域的多个成功发布。Kannan先生在马德拉斯大学（University of Madras）获得化学学士学位，在东卡罗莱纳大学（East Carolina University）获得工商管理硕士学位。
Raj Kannan became our Chief Executive Officer and joined our Board of Directors on June 17 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. “Kiniksa” (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.- Raj Kannan于2019年6月17日成为我们的首席执行官并加入我们的董事会。Kannan先生自2018年7月起从KiniksaPharmaceuticals，Ltd.Kiniksa”；（纳斯达克股票代码:KNSA）加入我们公司，担任首席商务官。在该职位上，他负责建立和领导公司的商业运营，包括销售、市场营销、业务分析和市场准入功能。任职Kiniksa公司之前，他曾担任Merck KGaA公司的神经学和免疫学（“；n&i”；）业务特许经营全球主管，在那里他负责20亿美元的年收入。在该职位上，他成功领导了Mavenclad（多发性硬化症的口服小分子）的推出。他还担任N&I特许经营领导团队主席，该团队负责推进免疫学管道资产，优先考虑投资组合组合，并在开发资产之间分配资源。在Merck KGaA之前，Kannan先生在Boehringer Ingelheim（“；Boehringer”；）工作了十年，在美国，加拿大和德国担任越来越重要的职务，包括心血管专营权的全球营销主管，在那里他负责超过35亿美元的年收入。任职Boehringer公司之前，他曾任职Merck and Co.近十年，担任多种职务，从现场销售到美国高级营销经理。Kannan先生领导或支持了在美国和全球治疗领域的多个成功发布。Kannan先生在马德拉斯大学（University of Madras）获得化学学士学位，在东卡罗莱纳大学（East Carolina University）获得工商管理硕士学位。
- Raj Kannan became our Chief Executive Officer and joined our Board of Directors on June 17 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. “Kiniksa” (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.
- William Ludlam
William Ludlam自2017年1月以来一直担任我们临床开发和医疗事务高级副总裁，，并自2015年8月以来一直在公司担任越来越重要的职务。在加入我们之前，他曾担任多种职务，最终于2012年3月至2015年8月担任跨国制药公司Novartis AG NYSE:NVS的高级医疗主管。Ludlam博士还在瑞典医疗中心（Swedish Medical Center）的西雅图垂体中心和俄勒冈州波特兰的俄勒冈健康与科学大学（Oregon Health&Sciences University）的垂体单元创立并担任医学总监。Ludlam博士于1995年获得叶史瓦大学阿尔伯特·爱因斯坦医学院（Albert Einstein College of Medicine）的医学博士学位和博士学位（发育神经科学），并于1986年获得惠蒂尔学院（Whittier College）的化学学士学位。
William Ludlam has been our Senior Vice President, Clinical Development and Medical Affairs since January 2017 and has served the Company in roles of increasing responsibility since August 2015. Prior to joining us, he served in various roles culminating in the position of Senior Medical Director of Novartis AG NYSE: NVS, a multinational pharmaceutical company, from March 2012 to August 2015. Dr. Ludlam also founded and served as Medical Director of the Seattle Pituitary Center at the Swedish Medical Center and the Pituitary Unit at the Oregon Health & Sciences University in Portland, Oregon. Dr. Ludlam received his M.D. and Ph.D. (Developmental Neuroscience) from the Albert Einstein College of Medicine of Yeshiva University in 1995 and a B.S. in Chemistry from Whittier College in 1986.- William Ludlam自2017年1月以来一直担任我们临床开发和医疗事务高级副总裁，，并自2015年8月以来一直在公司担任越来越重要的职务。在加入我们之前，他曾担任多种职务，最终于2012年3月至2015年8月担任跨国制药公司Novartis AG NYSE:NVS的高级医疗主管。Ludlam博士还在瑞典医疗中心（Swedish Medical Center）的西雅图垂体中心和俄勒冈州波特兰的俄勒冈健康与科学大学（Oregon Health&Sciences University）的垂体单元创立并担任医学总监。Ludlam博士于1995年获得叶史瓦大学阿尔伯特·爱因斯坦医学院（Albert Einstein College of Medicine）的医学博士学位和博士学位（发育神经科学），并于1986年获得惠蒂尔学院（Whittier College）的化学学士学位。
- William Ludlam has been our Senior Vice President, Clinical Development and Medical Affairs since January 2017 and has served the Company in roles of increasing responsibility since August 2015. Prior to joining us, he served in various roles culminating in the position of Senior Medical Director of Novartis AG NYSE: NVS, a multinational pharmaceutical company, from March 2012 to August 2015. Dr. Ludlam also founded and served as Medical Director of the Seattle Pituitary Center at the Swedish Medical Center and the Pituitary Unit at the Oregon Health & Sciences University in Portland, Oregon. Dr. Ludlam received his M.D. and Ph.D. (Developmental Neuroscience) from the Albert Einstein College of Medicine of Yeshiva University in 1995 and a B.S. in Chemistry from Whittier College in 1986.
- Lee G. Giguere
Lee G.Giguere自2019年9月起担任我们的Vice President兼总法律顾问。在加入公司之前，他曾于2018年7月至2019年9月担任Karyopharm TherapeuticsInc.副总法律顾问兼助理秘书，并于2016年9月至2018年7月担任副总法律顾问兼助理秘书纳斯达克股票代码:KPTI，一家专注于肿瘤的制药公司。在加入Karyopharm TherapeuticsInc.之前，Giguere先生是《财富》500强医疗设备公司波士顿科学国际有限公司（纽约证券交易所代码:BSX）的高级证券和治理顾问。他的职业生涯始于任职Goodwin Procter LLP的商业法律部门，在那里他专注于代表上市公司从事证券法、公司治理事务和公司融资交易。Giguere先生在东北大学（Northeastern University）获得金融学学士学位，并在东北大学法学院（Northeastern University School of Law）获得法学博士学位。
Lee G. Giguere has been our Vice President, General Counsel since September 2019. Prior to joining the Company, he served as Deputy General Counsel and Assistant Secretary from July 2018 to September 2019 and Associate General Counsel and Assistant Secretary from September 2016 to July 2018 of Karyopharm Therapeutics Inc. NASDAQ: KPTI, an oncology-focused pharmaceutical company. Prior to joining Karyopharm Therapeutics Inc., Mr. Giguere was Senior Securities and Governance Counsel at Boston Scientific Corporation (NYSE: BSX), a Fortune 500 medical device company. Mr. Giguere began his professional career in the business law department of Goodwin Procter LLP where he concentrated his practice on representing public companies in connection with securities law and corporate governance matters and corporate finance transactions. Mr. Giguere received his B.S. in Finance from Northeastern University and his J.D. from Northeastern University School of Law.- Lee G.Giguere自2019年9月起担任我们的Vice President兼总法律顾问。在加入公司之前，他曾于2018年7月至2019年9月担任Karyopharm TherapeuticsInc.副总法律顾问兼助理秘书，并于2016年9月至2018年7月担任副总法律顾问兼助理秘书纳斯达克股票代码:KPTI，一家专注于肿瘤的制药公司。在加入Karyopharm TherapeuticsInc.之前，Giguere先生是《财富》500强医疗设备公司波士顿科学国际有限公司（纽约证券交易所代码:BSX）的高级证券和治理顾问。他的职业生涯始于任职Goodwin Procter LLP的商业法律部门，在那里他专注于代表上市公司从事证券法、公司治理事务和公司融资交易。Giguere先生在东北大学（Northeastern University）获得金融学学士学位，并在东北大学法学院（Northeastern University School of Law）获得法学博士学位。
- Lee G. Giguere has been our Vice President, General Counsel since September 2019. Prior to joining the Company, he served as Deputy General Counsel and Assistant Secretary from July 2018 to September 2019 and Associate General Counsel and Assistant Secretary from September 2016 to July 2018 of Karyopharm Therapeutics Inc. NASDAQ: KPTI, an oncology-focused pharmaceutical company. Prior to joining Karyopharm Therapeutics Inc., Mr. Giguere was Senior Securities and Governance Counsel at Boston Scientific Corporation (NYSE: BSX), a Fortune 500 medical device company. Mr. Giguere began his professional career in the business law department of Goodwin Procter LLP where he concentrated his practice on representing public companies in connection with securities law and corporate governance matters and corporate finance transactions. Mr. Giguere received his B.S. in Finance from Northeastern University and his J.D. from Northeastern University School of Law.
- Mark J. Fitzpatrick
Mark J. Fitzpatrick，自2011年5月起担任本公司首席财务官。从2007年7月至2011年5月，他担任Proteon Therapeutics的副总裁兼首席财务官，这是一家开发治疗肾病和血管疾病的药品的私营生物制药公司。从2005年8月至2007年5月，他担任RenaMed Biologics的副总裁，首席财务官，财务主管，和助理企业秘书。之前，他也曾担任以下公司的首席财务官：Dynogen Pharmaceuticals, Worldstreet Corporation ，Diacrin。担任上述职务之前，他在Repligen Corp担任了多个财务管理职位，也曾担任安达信公司的高级审计师。他获得了波士顿大学理科学士学位，并于1987年取得了马萨诸塞州联邦注册会计师证书。
Mark J. Fitzpatrick has been our President since October 2016 and previously served as our Chief Executive Officer and a member of our Board of Directors from October 2016 to June 2019 and Chief Financial Officer from June 2015 to October 2016. Prior to joining us, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. He also held the position of Chief Financial Officer at Proteon Therapeutics, Inc., RenaMed Biologics, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987.- Mark J. Fitzpatrick，自2011年5月起担任本公司首席财务官。从2007年7月至2011年5月，他担任Proteon Therapeutics的副总裁兼首席财务官，这是一家开发治疗肾病和血管疾病的药品的私营生物制药公司。从2005年8月至2007年5月，他担任RenaMed Biologics的副总裁，首席财务官，财务主管，和助理企业秘书。之前，他也曾担任以下公司的首席财务官：Dynogen Pharmaceuticals, Worldstreet Corporation ，Diacrin。担任上述职务之前，他在Repligen Corp担任了多个财务管理职位，也曾担任安达信公司的高级审计师。他获得了波士顿大学理科学士学位，并于1987年取得了马萨诸塞州联邦注册会计师证书。
- Mark J. Fitzpatrick has been our President since October 2016 and previously served as our Chief Executive Officer and a member of our Board of Directors from October 2016 to June 2019 and Chief Financial Officer from June 2015 to October 2016. Prior to joining us, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. He also held the position of Chief Financial Officer at Proteon Therapeutics, Inc., RenaMed Biologics, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987.